Fri, Aug 1, 2014, 8:19 AM EDT - U.S. Markets open in 1 hr 11 mins


% | $
Click the to save as a favorite.

Arena Pharmaceuticals, Inc. Message Board

oscar851 20 posts  |  Last Activity: Jul 30, 2014 9:00 AM Member since: Mar 10, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    SEC Investigating AF

    by jumbolaya23 Jul 30, 2014 8:30 AM
    oscar851 oscar851 Jul 30, 2014 9:00 AM Flag

    To save his #$%$ he will divulge all the Hedge Funds and MM he has been working with and one of them will be the sacrificial lamb!

    Sentiment: Strong Buy

  • Reply to

    Back up the truck

    by oscar851 Jul 14, 2014 9:43 AM
    oscar851 oscar851 Jul 14, 2014 10:48 AM Flag

    IMHO, it is basing a bottom now and the risk being out is high as I would be extremely surprised if this is not taken out by summers end. These small media plays offer huge potential for ad placement vehicles which is the currency of our days!

    Sentiment: Strong Buy

  • oscar851 by oscar851 Jul 14, 2014 9:43 AM Flag

    She now is ready to rip!

  • oscar851 by oscar851 Jul 6, 2014 10:02 AM Flag

    Well ladies headed to where I warned you all!

  • Reply to

    Watch this sell off in after hours!

    by jumbolaya23 Jul 3, 2014 11:20 AM
    oscar851 oscar851 Jul 3, 2014 11:33 AM Flag

    Will blow right past all stop limits for bad Monday surprize gap down!

    Sentiment: Sell

  • Reply to

    If she breaks $4.46 next stop $3.97

    by oscar851 Jul 1, 2014 11:56 AM
    oscar851 oscar851 Jul 1, 2014 2:47 PM Flag

    Why 11 million share dump May 8th and 27 million dump week of May 8th? Nothing has changed, this will head back to lows until revenue stream corrects/fills in.

  • hold on to your seats!

    Sentiment: Hold

  • oscar851 by oscar851 Jun 30, 2014 10:44 AM Flag

    Get your high ranking guy into company and then proceed shortly after with a buyout!

  • Reply to

    GSK needs Belviq Combo

    by jumbolaya23 Jun 27, 2014 1:06 PM
    oscar851 oscar851 Jun 27, 2014 1:11 PM Flag

    Actos was the tenth-best selling drug in the U.S. in 2008, with sales exceeding $2.4 billion.

    This is what will make Belviq the blockbuster and GSK knows this and that is why it is testing as Actos is known cancer drug that GSK currently combos metformin with and is looking to replace Actos with Lorcaserin!! $$$$$$$$$$$

    Sentiment: Buy

  • all testing Lorcaserin with combo's. They all have chosen the safest and effective Lorcaserin over the others! HMMMMMMMMMMMMMM what comes next??? $$$$$$$$$$$$$$$

  • Reply to

    When good is told to be bad?

    by jumbolaya23 Jun 17, 2014 9:48 AM
    oscar851 oscar851 Jun 17, 2014 9:54 AM Flag

    They know the true value potential here, that is why they spend so much bashing and article generation to raise fear to get weak hands to capitulate. They want in and retail owns to much, they want your shares and know good times are fast approaching so they are making full court press for your shares!

    Sentiment: Strong Buy

  • Reply to

    Tax Loss carryover...HUGE

    by jumbolaya23 Jun 16, 2014 11:05 AM
    oscar851 oscar851 Jun 16, 2014 11:17 AM Flag

    GSK will prevail and soon.

    Sentiment: Strong Buy

  • Reply to

    Did FDA just flush a toilet?

    by jumbolaya23 Jun 11, 2014 9:15 AM
    oscar851 oscar851 Jun 11, 2014 9:19 AM Flag

    2 down 1 standing strong! no hurdles now road cleared for ARNA to run!

    Sentiment: Strong Buy

  • FDA reads it correctly, can never approve this #$%$!!!!

  • Q & A: How Safe is the Weight-Loss Drug Contrave?
    Rachael Rettner | December 13, 2010 02:11am ET



    A weight-loss drug called Contrave may be approved by the Food and Drug Administration in the coming weeks if the agency follows the advice of one of its panels, which recently weighed in on the matter.

    On Tuesday, the FDA panel voted 13 to 7 to recommend the drug for approval, according to news reports. The FDA often follows the recommendations of its panels, and is scheduled to make a final decision regarding Contrave by Jan. 31.

    The vote comes shortly after the administration denied approval of two other weight loss drugs: lorcaserin manufactured by Arena Pharmaceuticals Inc. and Qnexa made by Vivus Inc. Last month, Abbott Laboratories withdrew its weight loss drug Meridia from the U.S. market after studies linked it to an increased risk of heart attack and stroke.

    Experts have expressed concern over the new drug's potential side effects, which may pose hazards to the health of patients. For example, studies have linked the drug to seizures, said Dr. Pieter Cohen, an assistant professor of medicine at Harvard Medical School who researches the effects of dietary supplements.

    And the fact that pharmaceutical companies appear to be simply "repackaging" old pills in the hopes of generating a new solution for those who are overweight is also cause for concern, Cohen said. Contrave is made up of two medications — one antidepressant and one that treats addictions — that individually had been shown to lead to slight weight loss as a side effect.

    We spoke with Cohen about Contrave's safety, and whether such pills are really the way to go to tackle the obesity epidemic.

    Q: Were you surprised the FDA panel recommended Contrave for approval this week?

    A: Unfortunately, I can't say I was surprised. "Disappointed" would probably be a more accurate description.

    Q: Why were you disappointed?

    A: I think the panel recommendation advising to approve Contrave is a big step backward for people — patients waiting for an effective treatment for obesity, which we're certainly lacking.

    Q: Are there questions about the drug's safety?

    A: Even before thinking about the safety of the drug, it's interesting to take a look at whether or not it's going to be beneficial.

    The problem with Contrave is that we're, first off, just talking about a very small amount of weight loss — just over 4 percent in clinical trials. So if you're 225 pounds, we're talking about losing less than 10 pounds if you took this for an entire year. If you stopped after a year of taking Contrave, you would very likely gain the weight right back.

    So if you wanted to keep that 10 pounds off for a long period of time, you have to take the medicine for presumably the rest of your life. And we don’t have any safety data regarding its long-term health effects.

    We [also] don’t know if losing this modest amount of weight by taking this pill will provide any health benefit.

    Q: This drug is actually made of two different drugs. What might that mean for its side effects?

    A: So the bupropion, which has been widely used to treat depression…is well known to cause seizures.

    In the pharmaceutical [company] supported studies that are being used as evidence that this medication is effective, more patients who received the drug experienced seizures than patients who received placebo.

    This is quite remarkable, because the manufacturer was careful to exclude anyone with a known seizure disorder.

    So if you just imagine, when used more broadly, and when patients aren't carefully screened — or as carefully screened as they were in the clinical trials — that we're going to be seeing a lot more serious side effects, including seizures, if this pill were to be prescribed widely.

    Q: Are there also concerns about side effects on the heart?

    A: It's certainly concerning to see that the patients in the trials of Contrave had increases in blood pressure and increases in pulse.

    This could be a marker that it could have more serious cardiac side effects down the road.

    Specifically, bupropion, one of the two medications, has been reported to have caused death by heart attacks.

    Whether or not that is a causal relationship, bupropion actually caused those heart attacks, or it was just a coincidence, is not known. We wouldn't have the data about that for years, until another much larger study is completed.

    Q: But the panel also voted in favor of more studies to investigate whether the drug does confer heart risks.

    A: Right, but where does that leave us? That leaves us in a situation where, if its approved by the FDA — and heavily marketed as we would expect by the pharmaceutical company — we're going to have thousands, maybe millions of people who use this before we know whether or not it actually is causing more heart attacks [and] strokes.

  • Has moved to Orex first as pump and then dump just as they did with Vivus. They know these generic combos are BS and can't last! ARNA in the end will be the winner, especially when BelPhen arrives.

  • Reply to

    Only Two Clear Winners!

    by jumbolaya23 May 29, 2014 10:38 AM
    oscar851 oscar851 May 29, 2014 1:16 PM Flag

    Contrave potentially kills 40 out of a million users? FDA says screw Americans and potentially approves this? Heads should roll at the FDA. Will be a lawyers field day/money pot of gold with all the lawsuits!

  • estimated cost $180 million and potential for 40 deaths. FDA/Doctors "do no harm", this obviously violates that oath!

  • oscar851 by oscar851 May 21, 2014 9:24 AM Flag


    Esai offered 1/4 share for each ARNA share jack laughed, stated for Belviq alone would be 1/2 share and 15% royalty for patent life without extension.

  • Reply to

    Esai real motive is Type 2dm indication

    by jumbolaya23 May 20, 2014 11:13 AM
    oscar851 oscar851 May 20, 2014 11:37 AM Flag

    Diabetes epidemic in America has reached the peak.
    The huge burden of a diabetes has captured the United States - nowadays almost 13 percent of the population from the age of 20 years and more are sick of a diabetes, epidemiologists of National Health institute informs. The diabetes among senior Americans is especially extended...

    Esai smart as hell to buy now as this will own the marketplace for type 2 dm as indication is just around the corner!!!!

4.63+0.22(+4.75%)Jul 31 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.